vs
EXACT SCIENCES CORP（EXAS）与SCANSOURCE, INC.（SCSC）财务数据对比。点击上方公司名可切换其他公司
EXACT SCIENCES CORP的季度营收约是SCANSOURCE, INC.的1.1倍（$878.4M vs $766.5M），SCANSOURCE, INC.净利率更高（2.2% vs -9.8%，领先11.9%），EXACT SCIENCES CORP同比增速更快（23.1% vs 2.5%），EXACT SCIENCES CORP自由现金流更多（$120.4M vs $28.9M），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 0.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
ScanSource是全球领先的专业技术分销商，主营销售点系统、条码扫描设备、网络安全产品、云服务及通信解决方案，面向北美、拉美、欧洲的增值经销商、服务提供商及企业客户，覆盖零售、医疗、工业、公共部门等领域。
EXAS vs SCSC — 直观对比
营收规模更大
EXAS
是对方的1.1倍
$766.5M
营收增速更快
EXAS
高出20.6%
2.5%
净利率更高
SCSC
高出11.9%
-9.8%
自由现金流更多
EXAS
多$91.6M
$28.9M
两年增速更快
EXAS
近两年复合增速
0.9%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $766.5M |
| 净利润 | $-86.0M | $16.5M |
| 毛利率 | 70.1% | 13.4% |
| 营业利润率 | -9.4% | 2.3% |
| 净利率 | -9.8% | 2.2% |
| 营收同比 | 23.1% | 2.5% |
| 净利润同比 | 90.1% | -3.3% |
| 每股收益（稀释后） | $-0.45 | $0.75 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASSCSC
| Q4 25 | $878.4M | $766.5M | ||
| Q3 25 | $850.7M | $739.6M | ||
| Q2 25 | $811.1M | $812.9M | ||
| Q1 25 | $706.8M | $704.8M | ||
| Q4 24 | $713.4M | $747.5M | ||
| Q3 24 | $708.7M | $775.6M | ||
| Q2 24 | $699.3M | $746.1M | ||
| Q1 24 | $637.5M | $752.6M |
净利润EXASSCSC
| Q4 25 | $-86.0M | $16.5M | ||
| Q3 25 | $-19.6M | $19.9M | ||
| Q2 25 | $-1.2M | $20.1M | ||
| Q1 25 | $-101.2M | $17.4M | ||
| Q4 24 | $-864.6M | $17.1M | ||
| Q3 24 | $-38.2M | $17.0M | ||
| Q2 24 | $-15.8M | $16.1M | ||
| Q1 24 | $-110.2M | $12.8M |
毛利率EXASSCSC
| Q4 25 | 70.1% | 13.4% | ||
| Q3 25 | 68.6% | 14.5% | ||
| Q2 25 | 69.3% | 12.9% | ||
| Q1 25 | 70.8% | 14.2% | ||
| Q4 24 | 69.0% | 13.6% | ||
| Q3 24 | 69.4% | 13.1% | ||
| Q2 24 | 69.8% | 13.0% | ||
| Q1 24 | 70.0% | 12.6% |
营业利润率EXASSCSC
| Q4 25 | -9.4% | 2.3% | ||
| Q3 25 | -3.0% | 3.5% | ||
| Q2 25 | -0.3% | 3.3% | ||
| Q1 25 | -13.6% | 3.2% | ||
| Q4 24 | -122.8% | 2.5% | ||
| Q3 24 | -5.6% | 2.3% | ||
| Q2 24 | -3.8% | 2.9% | ||
| Q1 24 | -16.7% | 2.3% |
净利率EXASSCSC
| Q4 25 | -9.8% | 2.2% | ||
| Q3 25 | -2.3% | 2.7% | ||
| Q2 25 | -0.1% | 2.5% | ||
| Q1 25 | -14.3% | 2.5% | ||
| Q4 24 | -121.2% | 2.3% | ||
| Q3 24 | -5.4% | 2.2% | ||
| Q2 24 | -2.3% | 2.2% | ||
| Q1 24 | -17.3% | 1.7% |
每股收益（稀释后）EXASSCSC
| Q4 25 | $-0.45 | $0.75 | ||
| Q3 25 | $-0.10 | $0.89 | ||
| Q2 25 | $-0.01 | $0.87 | ||
| Q1 25 | $-0.54 | $0.74 | ||
| Q4 24 | $-4.69 | $0.70 | ||
| Q3 24 | $-0.21 | $0.69 | ||
| Q2 24 | $-0.09 | $0.66 | ||
| Q1 24 | $-0.60 | $0.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $83.5M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $910.9M |
| 总资产 | $5.9B | $1.7B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASSCSC
| Q4 25 | $964.7M | $83.5M | ||
| Q3 25 | $1.0B | $124.9M | ||
| Q2 25 | $858.4M | $126.2M | ||
| Q1 25 | $786.2M | $146.3M | ||
| Q4 24 | $1.0B | $110.5M | ||
| Q3 24 | $1.0B | $145.0M | ||
| Q2 24 | $946.8M | $185.5M | ||
| Q1 24 | $652.1M | $159.1M |
股东权益EXASSCSC
| Q4 25 | $2.4B | $910.9M | ||
| Q3 25 | $2.5B | $914.0M | ||
| Q2 25 | $2.5B | $906.4M | ||
| Q1 25 | $2.4B | $901.7M | ||
| Q4 24 | $2.4B | $900.7M | ||
| Q3 24 | $3.2B | $920.9M | ||
| Q2 24 | $3.2B | $924.3M | ||
| Q1 24 | $3.1B | $944.1M |
总资产EXASSCSC
| Q4 25 | $5.9B | $1.7B | ||
| Q3 25 | $5.9B | $1.7B | ||
| Q2 25 | $5.8B | $1.8B | ||
| Q1 25 | $5.7B | $1.7B | ||
| Q4 24 | $5.9B | $1.7B | ||
| Q3 24 | $6.7B | $1.8B | ||
| Q2 24 | $6.7B | $1.8B | ||
| Q1 24 | $6.4B | $1.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | $30.8M |
| 自由现金流经营现金流 - 资本支出 | $120.4M | $28.9M |
| 自由现金流率自由现金流/营收 | 13.7% | 3.8% |
| 资本支出强度资本支出/营收 | 3.6% | 0.3% |
| 现金转化率经营现金流/净利润 | — | 1.87× |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASSCSC
| Q4 25 | $151.7M | $30.8M | ||
| Q3 25 | $219.9M | $23.2M | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | $66.1M | ||
| Q4 24 | $47.1M | $-6.2M | ||
| Q3 24 | $138.7M | $44.8M | ||
| Q2 24 | $107.1M | — | ||
| Q1 24 | $-82.3M | $160.2M |
自由现金流EXASSCSC
| Q4 25 | $120.4M | $28.9M | ||
| Q3 25 | $190.0M | $20.8M | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | $64.6M | ||
| Q4 24 | $10.7M | $-8.2M | ||
| Q3 24 | $112.6M | $42.5M | ||
| Q2 24 | $71.2M | — | ||
| Q1 24 | $-120.0M | $157.7M |
自由现金流率EXASSCSC
| Q4 25 | 13.7% | 3.8% | ||
| Q3 25 | 22.3% | 2.8% | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | 9.2% | ||
| Q4 24 | 1.5% | -1.1% | ||
| Q3 24 | 15.9% | 5.5% | ||
| Q2 24 | 10.2% | — | ||
| Q1 24 | -18.8% | 21.0% |
资本支出强度EXASSCSC
| Q4 25 | 3.6% | 0.3% | ||
| Q3 25 | 3.5% | 0.3% | ||
| Q2 25 | 5.2% | 0.3% | ||
| Q1 25 | 4.4% | 0.2% | ||
| Q4 24 | 5.1% | 0.3% | ||
| Q3 24 | 3.7% | 0.3% | ||
| Q2 24 | 5.1% | 0.2% | ||
| Q1 24 | 5.9% | 0.3% |
现金转化率EXASSCSC
| Q4 25 | — | 1.87× | ||
| Q3 25 | — | 1.17× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.79× | ||
| Q4 24 | — | -0.36× | ||
| Q3 24 | — | 2.64× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 12.51× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
SCSC
| Products And Services | $723.4M | 94% |
| Intelisys Advisory | $25.0M | 3% |
| Recurring Revenue | $18.2M | 2% |
